chrisvoncsefalvay/vaers-outcomes huggingface dataset:
expirienced tingling; numbness on my right side, specifically my fingers\ my arm is numb/my neck and side of my head are numb; Pinched nerves; This spontaneous case was reported by a consumer and describes the occurrence of PARAESTHESIA (expirienced tingling), HYPOAESTHESIA (numbness on my right side, specifically my fingers\ my arm is numb/my neck and side of my head are numb) and NERVE COMPRESSION (Pinched nerves) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PARAESTHESIA (expirienced tingling), HYPOAESTHESIA (numbness on my right side, specifically my fingers\ my arm is numb/my neck and side of my head are numb) and NERVE COMPRESSION (Pinched nerves). At the time of the report, PARAESTHESIA (expirienced tingling), HYPOAESTHESIA (numbness on my right side, specifically my fingers\ my arm is numb/my neck and side of my head are numb) and NERVE COMPRESSION (Pinched nerves) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications were not provided.  Treatment information was not provided.  Alternative cause of the events was reported as pinched nerves in his neck.   Most recent FOLLOW-UP information incorporated above includes: On 29-Jul-2021: Event and event outcome updated.
The next day she became flushed and had a headache.  She was sent home from work.
Swelling under the eyes; This spontaneous case was reported by a nurse (subsequently medically confirmed) and describes the occurrence of EYE SWELLING (Swelling under the eyes) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse reaction.  On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EYE SWELLING (Swelling under the eyes). The patient was treated with HYALURONIC ACID (RESTYLANE) on 03-Oct-2020 at an unspecified dose and frequency. At the time of the report, EYE SWELLING (Swelling under the eyes) outcome was unknown.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.
Started getting itchy, as I started scratching it started spreading little bumps and I have a rash by my armpit on the same arm that the vaccine got injected into (the left arm) also my right elbow is really dry and scabbing.
Pt. received shot at 1:47pm. Patient began feeling light headiness  and flushed at 1:50-1:55pm and put head down between legs and tried to control breathing. At 2pm pt was given 50mg of Benadryl and BP was 120/40, pulse 102. Patient was then sitting upright  with legs elevated and began sipping orange juice and water. Cold ice packs and/or wash cloths were applied to  back of neck.  At 2:12 patient feeling flushed again and put head back down between legs. EMS was contacted. At 2:17 pulse was 151/60. Pulse 74. Patient then was laid down with legs elevated.  At 2:25 BP was 173/102.  At 2:30 EMS arrived and then transported pt to ER.
2 days status post vaccines child refused to ambulate not seen.  3 days status post vaccine ambulating.  4 days status post vaccine developed rash d/w erythema multiforme.
Information has been received from a medical assistant on behalf of a physician concerning a male patient who in approximately April 2012 (within the last two months), was vaccinated with a dose of ZOSTAVAX (Merck) (dose, route and lot # not reported). Within "a couple of days" of receiving the vaccine the patient developed disseminated (all over the body) hives. The patient was hospitalized on unspecified dates at an unspecified facility for the hives, shortness of breath and an unspecified "chest condition". On an unknown date the patient also developed 2 chronic urticaria with angioedema for 6 weeks. The patient was given 2 months of prednisone. The patient was recently seen and prednisone had helped with resolution of AE (still currently resolving). The physician was still not totally convinced the AE were from the vaccine. It was asked if there was any data on the occurrence of disseminated (all over the body) hives following ZOSTAVAX (Merck) vaccination and persisting for months. Additional information has been requested.
Had 3 seizures - starting at approximately 6 hours after vaccination and 2nd at 10 hours - 3rd at approximately 13 hours - started on Phenobarbital at hospital and advised to avoid further Pertussis. 8/1/07-records received--New onset seizures. Eyes rolled back rhythmic tonic-clonic movements of head as well as all extremities. New onset seizure likely secondary to DTaP
Persistent pain in arm that is still recurring OTC pain relievers, cold/warm compresses.
pt recv vax 1SEP95 &  arrived in ER mom stated pt very irritable & had had a gen sz 830AM on 2SEP95;
This spontaneous report was received from a pharmacist and refers to a patient of unknown age and gender. No information about the patient's medical history, concurrent conditions, drug reactions or allergies and concomitant therapies was provided. On 03-FEB-2017 at  09:10, the patient was vaccinated with improperly stored VARIVAX injection (lot # M035142) ( expiration date, dose and route of administration were not reported). The vaccine underwent previous temperature excursions. The number of previous excursions, time frames and values of incorrect temperature were unknown. No adverse effects were reported. Digital data logger was used. Product quality complaint was not involved. This is one of several reports received from the same reporter. Additional information has been requested.; Sender's Comments: US-009507513-1701USA008441: US-009507513-1704USA000389: US-009507513-1704USA000390: US-009507513-1704USA000391: US-009507513-1704USA000392: US-009507513-1704USA000393: US-009507513-1704USA000394: US-009507513-1704USA000395: US-009507513-1704USA000396: US-009507513-1704USA000397: US-009507513-1704USA000398: US-009507513-1704USA000399: US-009507513-1704USA000400: US-009507513-1704USA000401: US-009507513-1704USA000402: US-009507513-1704USA000403: US-009507513-1704USA000404: US-009507513-1704USA000405: US-009507513-1704USA000406: US-009507513-1704USA000407: US-009507513-1704USA000408: US-009507513-1704USA000410: US-009507513-1704USA000411: US-009507513-1704USA000412: US-009507513-1704USA000413: US-009507513-1704USA000414: US-009507513-1704USA000415: US-009507513-1704USA000416: US-009507513-1704USA000417: US-009507513-1704USA000418: US-009507513-1704USA000419: US-009507513-1704USA000420: US-009507513-1704USA000421: US-009507513-1704USA000422: US-009507513-1704USA000423: US-009507513-1704USA000424: US-009507513-1704USA000425: US-009507513-1704USA000426: US-009507513-1704USA000427: US-009507513-1704USA000428: US-009507513-1704USA000429: US-009507513-1704USA000430: US-009507513-1704USA000431: US-009507513-1704USA000432: US-009507513-1704USA000433: US-009507513-1704USA000434: US-009507513-1704USA000435: US-009507513-1704USA000436: US-009507513-1704USA000437: US-009507513-1704USA000438: US-009507513-1704USA000439: US-009507513-1704USA000440: US-009507513-1704USA000441: US-009507513-1704USA000442: US-009507513-1704USA000443: US-009507513-1704USA000444: US-009507513-1704USA000445: US-009507513-1704USA000446: US-009507513-1704USA000447: US-009507513-1704USA000448: US-009507513-1704USA000449: US-009507513-1704USA000450: US-009507513-1704USA000451: US-009507513-1704USA000452: US-009507513-1704USA000453: US-009507513-1704USA000454: US-009507513-1704USA000455: US-009507513-1704USA000456: US-009507513-1704USA000457
ringing in  ear; head spinning; heart murmur; pleural effusion; nerve pain; dehydration; nausea; vomiting; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of NEURALGIA (nerve pain), DEHYDRATION (dehydration), VERTIGO (head spinning), CARDIAC MURMUR (heart murmur) and PLEURAL EFFUSION (pleural effusion) in a 60-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 047A21A and 014M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Diabetes and Heart disorder. Concomitant products included METFORMIN for Diabetes, LISINOPRIL for Heart disorder.   On 01-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 24-May-2021, the patient experienced NEURALGIA (nerve pain) and PLEURAL EFFUSION (pleural effusion). In 2021, the patient experienced DEHYDRATION (dehydration), NAUSEA (nausea) and VOMITING (vomiting). On 09-Jul-2021, the patient experienced VERTIGO (head spinning) and CARDIAC MURMUR (heart murmur). On an unknown date, the patient experienced TINNITUS (ringing in  ear). The patient was treated with MECLIZINE [MECLOZINE] ongoing since an unknown date for Head spinning, at a dose of 1 dosage form; TRAMADOL ongoing since an unknown date for Nerve pain, at a dose of 1 dosage form; CELECOXIB for Muscle relaxant, at a dose of 1 dosage form; PREDNISONE for Nausea and Vomiting, at a dose of 1 dosage form and ONDANSETRON for Nausea and Vomiting, at a dose of 1 dosage form. At the time of the report, NEURALGIA (nerve pain), DEHYDRATION (dehydration), VERTIGO (head spinning), CARDIAC MURMUR (heart murmur), PLEURAL EFFUSION (pleural effusion), TINNITUS (ringing in  ear), NAUSEA (nausea) and VOMITING (vomiting) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Computerised tomogram: abnormal (abnormal) fluid build up in chest.         Patient took prednisone for 4-5 days which causes nausea and vomiting. Patient undergone MRI scan.   This case was linked to MOD-2021-257861 (Patient Link).
EXTREME immediate pain, feeling as if I'd pass out.. immediate increased nasal secretions within 10 minutes of receiving vaccine, followed by extreme pain for entire day, complete shoulder front and back of shoulder radiating halfway up neck pain, severe fatigue followed the next day with inability to get out of bed, moderate flu like symptoms.. chills x three weeks but no fever, unable to use or lift arm due to pain, muscles felt like overused as if every muscle in shoulder was pulled.. unable to lay on that side, unable to lift anything, and use of arm limited as of 10/27/12 and continues.
Fever and chills with sensation of skin being hot began 15 hours post injection. Took 400mg ibuprofen every 4-6 hours. Exceeded six hours without ibuprofen and fever returned 27 hours post injection. Took 400 mg ibuprofen and immediately became nauseous. Began walking up stairs and lost consciousness and seized/convulsed briefly (witnessed by my wife). Upon regaining consciousness, I was immediately aware of what happened, date, time, etc., so we did not seek medical attention. Continued ibuprofen every 4-6 hours. On two occasions post loss of consciousness, the first within an hour and the second four hours later, I felt tingly and smelled a strong scent of acetone or ammonia. Both passed quickly. Fever broke soon after second incidence. All symptoms were gone within 48 hours of injection.
Vaccine was administered at 2:54 PM on 16 NOV 2021 and was initially punctured at 10:30 AM the previous day.; Initially punctured at 10:30 AM the previous day, being left at room temperature for approximately 28.5 hours.; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine was administered at 2:54 PM on 16 NOV 2021 and was initially punctured at 10:30 AM the previous day.) and PRODUCT STORAGE ERROR (Initially punctured at 10:30 AM the previous day, being left at room temperature for approximately 28.5 hours.) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 034F21A, 014C21A and 001B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 29-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 16-Nov-2021 at 2:54 AM, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In November 2021, the patient experienced PRODUCT STORAGE ERROR (Initially punctured at 10:30 AM the previous day, being left at room temperature for approximately 28.5 hours.). On 16-Nov-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine was administered at 2:54 PM on 16 NOV 2021 and was initially punctured at 10:30 AM the previous day.). In November 2021, PRODUCT STORAGE ERROR (Initially punctured at 10:30 AM the previous day, being left at room temperature for approximately 28.5 hours.) had resolved. On 16-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Vaccine was administered at 2:54 PM on 16 NOV 2021 and was initially punctured at 10:30 AM the previous day.) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   It was reported that the booster dose of the vaccine was administered at 2:54 PM on 16 Nov 2021 and was initially punctured at 10:30 AM the previous day, being left at room temperature for approximately 28.5 hours. No symptoms were reported. No concomitant medications provided. No treatment medications received.
Body aches, chills,   Headache in neck/base of head, leg aches, injection site soreness,  Very swollen lymph nodes in armpit, injection site swelling, fatigue, slight fever(on and off)
Pregnant; This spontaneous prospective pregnancy case was reported by a patient and describes the occurrence of MATERNAL EXPOSURE BEFORE PREGNANCY (Pregnant) in a 32-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 210120031) for COVID-19 vaccination.     The patient's past medical history included Human papilloma virus infection in November 2020. Previously administered products included for an unreported indication: HPV VACCINE (She had the complete series of the HPV vaccine). Concurrent medical conditions included Pregnancy since 15-Sep-2020. Concomitant products included IRON FERROUS and MULTIVITAMIN [VITAMINS NOS] for an unknown indication.    On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 15-Sep-2020 and the estimated date of delivery was 22-Jun-2021. On 20-Jan-2021, the patient experienced MATERNAL EXPOSURE BEFORE PREGNANCY (Pregnant). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  eighteenth week of the pregnancy.  On 20-Jan-2021, MATERNAL EXPOSURE BEFORE PREGNANCY (Pregnant) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Information has been received from a registered nurse concerning multiple unspecified patients of unknown age and gender. The patient's medical histories and concurrent conditions were not provided. On unknown dates, the patients were vaccinated with multiple improperly stored (Oka-Merck) PROQUAD (dose and route were unknown, lot # L051098, expiration date 17-JUN-2017; lot # M002053, expiration date 11-JUL-2017; lot # L046506, expiration date 17-MAY-2017 and lot # M006102, expiration date 01-AUG-2017 (therapy type is rHA). The nurse provided the details of excursion: temperature mas of -7.2 degree centigrade for a cumulative time frame of 9 hours and 17 minutes and a max of -12.6 degree centigrade for cumulative time frame of 6 hours and 10 minutes. The current temperature was -14.1 degree centigrade, which was still out of range at the time of the report. The vaccines were also exposed to a previous excursion of -4 degree centigrade for 3 hours. No adverse effects reported. This is one of several reports received from the same reporter. Additional information has been requested.
Approximately 5 minutes after receiving vaccine, started complaining about feeling weak, ears "feeling weird", spots in visual field, pale. 1-2 minutes later while seated - head fell back, eyes rolled backwards, lost consciousness for ~ 2 - 3 seconds then came out of it quickly, felt better, conversing appropriately. BP 96/48 @ 4:30 pm, 98/72 @ 4:40 pm, pulse "in the 60s" per nurse's note. Other nurse nearby stated that she heard her say her throat felt funny when she was first complaining. Pt states "it was just for a minute then it went away".  Sent by ambulance to ER. Went to school the next day feeling fine. Has appt with allergist in January 2018 to evaluate for future flu vaccine.
pt recv vax 2OCT95 & several hr later pt devel gen rash, described as looking like bug bites;tx w/an unspecified inj in outpatient clinic 4OCT95 but sx persisted;pt adm to hosp later that day;d/c dx unk;
three patients were administered with only the adjuvant part of Shingrix; three patients were administered with only the adjuvant part of Shingrix; This case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a patient who received Herpes zoster (Shingrix) (batch number M397F, expiry date 23rd April 2023) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown.   Additional Information: GSK Receipt Date: 20-APR-2022 Reporter's Comments: A medical assistant reported that the patient was administered with only the adjuvant part of Shingrix. The medical assistant discovered the error but she could not provide any details about the patient administered with a partial dose because that information was still not available. There were 3 patients who received only adjuvant part out of total 10 patients. This last situation made that all the patient would be revaccinated, and considering this, 7 patients would receive a third dose of Shingrix. The reporter consented to follow up. Additional Supportive Information: The patient was administered with only the adjuvant part of Shingrix, which led to Inappropriate preparation of medication and inappropriate dose of vaccine administered. The case is one of 4 cases, reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2022AMR067807:same reporter US-GLAXOSMITHKLINE-US2022AMR071123:same reporter US-GLAXOSMITHKLINE-US2022067585:same reporter
mRNA vaccine induced myocarditis; This literature-non-study case was reported in a literature article and describes the occurrence of MYOCARDITIS (mRNA vaccine induced myocarditis) in a 59-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.        Concurrent medical conditions included Hypertension and Prediabetes.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced MYOCARDITIS (mRNA vaccine induced myocarditis) (seriousness criterion medically significant). At the time of the report, MYOCARDITIS (mRNA vaccine induced myocarditis) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Cardiac function test: elevated (High) Elevated. On an unknown date, Magnetic resonance imaging heart: myocarditis Myocarditis.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered MYOCARDITIS (mRNA vaccine induced myocarditis) to be related.    Patient has undiagnosed respiratory illness 6 months prior presentation. But further workup was negative for significant coronary artery disease (CAD) and their disease course was mild.  Concomitant were not reported. This is a literature case concerning a 59-year-old male patient with a medical history of hypertension and glucose tolerance impairment, who experienced the serious expected AESI event of myocarditis. The event occurred within 24 hours after the second dose of the mRNA-1273 vaccine. The rechallenge was not applicable, as the event was reported after the second dose and no information on additional dosing available. The medical history of hypertension and glucose tolerance impairment considered as confounders. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Additional information has been requested.   This case was linked to MOD-2022-460654 (Patient Link).   Reporter did not allow further contact; Sender's Comments: This is a literature case concerning a 59-year-old male patient with a medical history of hypertension and glucose tolerance impairment, who experienced the serious expected AESI event of myocarditis. The event occurred within 24 hours after the second dose of the mRNA-1273 vaccine. The rechallenge was not applicable, as the event was reported after the second dose and no information on additional dosing available. The medical history of hypertension and glucose tolerance impairment considered as confounders. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Additional information has been requested.
Pale, hyporesponsive 6 hrs p/DTP/HIBTITER & OPV were given;
aching pain @ inj site (upper arm) when moving arm it hurts-lower part of arm feels like it has a spain
This spontaneous report was received from a 47 year old female patient who was reporting on herself. On 30-MAY-2014 the patient was vaccinated with a dose of ZOSTAVAX (vial, dose, route of administration, lot number and expiration date were not reported). The patient was outside of the age indication for ZOSTAVAX. Additional information has been requested.
pt exp fullness in ear;MRI;Dx w/unilateral hearing loss;f/u pt unable to walk w/o staggering to one side;dec hearing w/tinnitus;saw ENT; 40% hearing loss;tx:prednisone & meclizine hcl w/temporary relief; improving by July
Vaccine given on a Friday. Pt reports that evening started having headache, back/neck pain, fever and chills and that she stayed in bed Saturday and Sunday with these symptoms. She also had arm swelling which started "that day" of the injection and by the next morning was the entire upper arm down to her elbow, couldn't sleep in that side, limited use of arm due to pain for next 2 days.  She took ibuprofen for this. Reported it to office on 7/15/19 at 835 am and said "most of it is over, the swelling has gone down, just wanted us to know"